Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram,
followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for
persistent symptoms.